AtriCure and Baheal Group Establish Partnership and China Distribution Agreement

AtriCure Inc., an innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the company’s previous distributor in China.
 
“We are pleased to have formed this new partnership with Baheal,” said Michael Carrel, AtriCure’s president and CEO. “With Baheal’s stellar reputation, their size and scale, combined with our market-leading devices, we are well positioned to establish a foundation for future growth in China.”
 
AtriCure has been selling its surgical ablation devices in China for the past 14 years. During that time, several of China’s leading hospitals have adopted AtriCure devices, and in addition, the company expects to pursue new product approvals over the next several years to eventually bring its full portfolio of surgical ablation and left atrial appendage management devices into the market.
 
“At Baheal, we’re continuously looking for ways to grow and expand our business,” said Fu Gang, chairman of Baheal Pharmaceutical Group. “We believe that there is vast opportunity to treat patients and the market remains underpenetrated, and we’re confident that together, we are well positioned to grow and help more patients in China affected by Atrial Fibrillation.”
 
AtriCure Inc. provides technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator Synergy Ablation System is the first and only medical device to receive U.S. Food and Drug Administration approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. AtriCure.com
 
Founded in 2005, BAHEAL Pharmaceutical Group is a group enterprise devoted to the resource innovation and integration platform in the health industry. Driven by the world’s intelligent information technologies, relying on its capability in health brand operation and management and building on its industry resource integration abilities, the Group has been digging deep in China’s medical and healthcare industry for more than a decade, providing optimized solutions for all links along the big health industry chain through the global brand ecosystem, intelligent application ecosystem, medical service ecosystem and investment ecosystem under its flag.